Literature DB >> 1906293

Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle.

P Mullen1, W N Scott, W R Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1906293      PMCID： PMC1972522          DOI： 10.1038/bjc.1991.203

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  18 in total

1.  Treatment of breast cancer with gonadotropin-releasing hormone.

Authors:  A Manni; R Santen; H Harvey; A Lipton; D Max
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

2.  Growth inhibitory effect of LH-RH analogs on human breast cancer cells.

Authors:  G Scambia; P B Panici; G Baiocchi; L Perrone; C Gaggini; S Iacobelli; S Mancuso
Journal:  Anticancer Res       Date:  1988 Jan-Feb       Impact factor: 2.480

3.  A new class of contraceptives?

Authors:  H M Fraser
Journal:  Nature       Date:  1982-04-01       Impact factor: 49.962

4.  Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.

Authors:  M Fekete; J L Wittliff; A V Schally
Journal:  J Clin Lab Anal       Date:  1989       Impact factor: 2.352

Review 5.  Clinical applications of LHRH analogues.

Authors:  H M Fraser; D T Baird
Journal:  Baillieres Clin Endocrinol Metab       Date:  1987-02

6.  A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment.

Authors:  B J Slotman; L G Poels; B R Rao
Journal:  Anticancer Res       Date:  1989 Jan-Feb       Impact factor: 2.480

7.  Gonadotropin-releasing hormone binding sites in human breast carcinoma.

Authors:  K A Eidne; C A Flanagan; R P Millar
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

8.  Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer.

Authors:  K J Walker; A Turkes; M R Williams; R W Blamey; R I Nicholson
Journal:  J Endocrinol       Date:  1986-11       Impact factor: 4.286

9.  The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.

Authors:  M R Williams; K J Walker; A Turkes; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1986-05       Impact factor: 7.640

10.  Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.

Authors:  P N Plowman; R I Nicholson; K J Walker
Journal:  Br J Cancer       Date:  1986-12       Impact factor: 7.640
View more
  7 in total

1.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity.

Authors:  I Pályi; B Vincze; S Lovas; I Mezö; J Pató; A Kálnay; G Turi; D Gaál; R Mihalik; I Péter; I Teplán; R F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

3.  Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues.

Authors:  A Kálnay; I Pályi; B Vincze; R Mihalik; I Mezõ; J Pató; J Seprõdi; S Lovas; R F Murphy
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

4.  Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.

Authors:  K H Baumann; L Kiesel; M Kaufmann; G Bastert; B Runnebaum
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells.

Authors:  G Sica; F Iacopino; G Robustelli della Cuna; P Marchetti; L Marini
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Fertility preservation in reproductive-age women facing gonadotoxic treatments.

Authors:  J Roberts; R Ronn; N Tallon; H Holzer
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

7.  GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor.

Authors:  Madelaine Cho-Clark; Darwin O Larco; Nina N Semsarzadeh; Florencia Vasta; Shaila K Mani; T John Wu
Journal:  Mol Endocrinol       Date:  2013-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.